Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted EBT Margin of 390.98% for Q1 2026, down 60.42% on a QoQ basis from 243.72% in Q4 2025, and down 17329.0% year-over-year from N/an in Q1 2025.
Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' EBT Margin history runs 7 years deep, the most recent figure standing at 390.98% for Q1 2026.
- Quarterly EBT Margin fell 17329.0% year-over-year to 390.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 211.5% (down 701.0% YoY) and the FY2025 annual result came in at 184.3%, up 5684.0% from the prior year.
- EBT Margin was 390.98% for Q1 2026 at Ginkgo Bioworks Holdings, down from 243.72% in the prior quarter.
- Across five years, EBT Margin topped out at 63.76% in Q3 2024 and bottomed at 1009.31% in Q3 2022.
- A 5-year average of 319.66% and a median of 245.99% in 2024 frame the typical range for EBT Margin.
- Peak annual rise in EBT Margin reached 89018 bps in 2022, while the deepest fall reached 87709 bps in 2022.
- Ginkgo Bioworks Holdings' EBT Margin stood at 191.13% in 2022, then surged by 54 bps to 87.17% in 2023, then slumped by 182 bps to 245.99% in 2024, then advanced by 1 bps to 243.72% in 2025, then sank by 60 bps to 390.98% in 2026.
- Business Quant data shows DNA's EBT Margin at 390.98% in Q1 2026, 243.72% in Q4 2025, and 207.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -390.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -390.98% |
| Dec 31, 2025 | -243.72% |
| Sep 30, 2025 | -207.93% |
| Jun 30, 2025 | -122.13% |
| Mar 31, 2025 | -217.69% |
| Dec 31, 2024 | -245.99% |
| Sep 30, 2024 | -63.76% |
| Jun 30, 2024 | -386.06% |
| Mar 31, 2024 | -437.17% |
| Dec 31, 2023 | -87.17% |
| Sep 30, 2023 | -546.48% |
| Jun 30, 2023 | -215.03% |
| Mar 31, 2023 | -253.88% |
| Dec 31, 2022 | -191.13% |
| Sep 30, 2022 | -1,009.31% |
| Jun 30, 2022 | -463.71% |
| Mar 31, 2022 | -351.99% |
| Dec 31, 2021 | -1,081.31% |
| Sep 30, 2021 | -132.21% |
| Jun 30, 2021 | -125.80% |